| Literature DB >> 25551236 |
Alan F Schatzberg, Pierre Blier, Larry Culpepper, Rakesh Jain, George I Papakostas, Michael E Thase.
Abstract
Six clinicians provide an overview of the serotonergic antidepressant vortioxetine, which was recently approved for the treatment of major depressive disorder in adults. They discuss the pharmacologic profile and receptor-mediated effects of vortioxetine in relation to potential outcomes. Additionally, they summarize the clinical trials, which demonstrate vortioxetine's efficacy, and discuss findings related to safety and tolerability that have high relevance to patient compliance. © Copyright 2014 Physicians Postgraduate Press, Inc.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25551236 DOI: 10.4088/JCP.14027ah1
Source DB: PubMed Journal: J Clin Psychiatry ISSN: 0160-6689 Impact factor: 4.384